Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

AI startups can show explosive growth, like reaching millions in ARR in months, before any customers have renewed. This makes traditional traction analysis difficult for VCs, who must underwrite deals at high valuations based on uncertain, potentially ephemeral, customer signals.

Related Insights

The traditional VC growth metric of tripling revenue annually is being dwarfed by AI. In some AI-native markets, VCs now expect startups to achieve 10x revenue growth in a single year, dramatically increasing pressure and changing valuation dynamics.

In an era of high customer demand for AI solutions, a lack of early traction is a critical warning sign. The combination of market pull and rapid development cycles means successful products should demonstrate momentum almost immediately. If it's not working fast, it's likely not working.

For AI companies experiencing explosive growth like Harvey (tripling ARR in a year), traditional TAM analysis is an obstacle, not a tool. Such growth signals the company is capturing a new budget pool (e.g., labor costs) that dwarfs the existing software market. In these cases, the revenue trajectory itself becomes the best indicator of the true TAM.

Unlike traditional software where growth implied de-risking, AI companies can achieve billion-dollar revenues without validating unit economics. This breaks the historical inverse relationship between scale and risk, creating a paradigm where larger companies are not necessarily safer investments.

Lin warns that much of today's AI revenue is 'experimental,' where customers test solutions without long-term commitment. He calls annualizing this pilot revenue 'a joke.' He advises founders to prioritize slower, high-quality, high-retention revenue over fast, low-quality growth that will eventually churn.

The narrative of "0 to $100M in a year" often reflects a startup's dependence on a larger, fast-growing customer (like an AI foundation model company) rather than intrinsic product superiority. This growth is a market anomaly, similar to COVID testing labs, and can vanish as quickly as it appeared when competition normalizes prices and demand shifts.

AI companies raise subsequent rounds so quickly that little is de-risked between seed and Series B, yet valuations skyrocket. This dynamic forces large funds, which traditionally wait for traction, to compete at the earliest inception stage to secure a stake before prices become untenable for the risk involved.

In the current AI hype cycle, a common mistake is valuing startups as if they've already achieved massive growth, rather than basing valuation on actual, demonstrated traction. This "paying ahead of growth" leads to inflated valuations and high risk, a lesson from previous tech booms and busts.

The established SaaS growth benchmark of "triple, triple, double, double" is no longer sufficient in the AI era. To secure Series A and B funding today, VCs expect AI-native companies to demonstrate much faster initial traction, closer to 5x, then 4.5x year-over-year revenue growth.

Unlike previous tech cycles where early revenue was a strong signal, the current AI hype creates significant "experimental demand." Companies will try, pay for, and even renew products that don't fully work. Investors must look beyond revenue to assess true product-market fit.